Bladder cancer

Assessing the conundrum of microscopic haematuria

Article metrics

The compliance of physicians to current guidelines for asymptomatic microhaematuria is limited and the evidence supporting asymptomatic microhaematuria as an effective screening tool for the early detection of bladder cancer is weak. Medical or surgical treatment is indicated in 13–35% of patients with asymptomatic microhaematuria, albeit mostly for benign conditions, which are more commonly the cause. The high prevalence of asymptomatic microhaematuria in the general population means that this condition poses a considerable challenge to the health-care system.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Davis, R. et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J. Urol. 188 (Suppl.), 2473–2481 (2012).

  2. 2

    Schmitz-Drager, B. J. et al. Microhematuria assessment an IBCN consensus — based upon a critical review of current guidelines. Urol. Oncol. 34, 437–451 (2016).

  3. 3

    Burger, M. et al. Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol. 64, 846–854 (2013).

  4. 4

    Richards, K. A., Ham, S., Cohn, J. A. & Steinberg, G. D. Urinary tract infection-like symptom is associated with worse bladder cancer outcomes in the Medicare population: implications for sex disparities. Int. J. Urol. 23, 42–47 (2016).

  5. 5

    Cohn, J. A. et al. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer 120, 555–561 (2014).

  6. 6

    Brehmer, M. Imaging for microscopic hematuria. Curr. Opin. Urol. 12, 155–159 (2002).

Download references

Author information

Correspondence to Gary D. Steinberg.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark